Recently, immune checkpoint inhibitors (ICIs) therapy has become a promising therapeutic
strategy with encouraging therapeutic outcomes due to their durable anti-tumor effects …

Triple-negative breast cancer (TNBC) is not a unique disease, encompassing multiple
entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite …

Hypoxia-inducible factors (HIFs) and the HIF-dependent cancer hallmarks angiogenesis and
metabolic rewiring are well-established drivers of breast cancer aggressiveness, therapy …

Background Angiogenesis is a key and early step in tumorigenesis, and is known as a
hallmark of solid tumors and a key promoter of tumor recurrence. Unlike normal tissue …

Anti-angiogenic therapies (AATs) are used to treat different types of cancers. However, their
success is limited owing to insufficient efficacy and resistance. Recently, single-cell omics …

Background Immunotherapy has recently emerged as a treatment strategy which stimulates
the human immune system to kill tumor cells. Tumor immunotherapy is based on immune …

Cytokines play a critical role in regulating host immune response toward cancer and
determining the overall fate of tumorigenesis. The tumor microenvironment is dominated …

In the later-line setting or for patients with PD-L1-negative tumors, immunotherapy-based
regimens remain ineffective against advanced triple-negative breast cancer (TNBC). In this …

Novel neoadjuvant therapy regimens are warranted for oral squamous cell carcinoma
(OSCC). In this phase I trial (NCT04393506), 20 patients with locally advanced resectable …

Angiogenesis is a vital process for the growth and dissemination of solid cancers. Numerous
molecular pathways are known to drive angiogenic switch in cancer cells promoting the …